Investigating how a specific protein affects the harmful traits of a common bacteria.
Official title: Equipment Supplement for 7R15GM150043-02: The role of master regulator NtrC in amyloid fibril dependent pathogenic traits of Pseudomonas aeruginosa
Funded at Eastern Washington University · NIH-11035787 · Data updated 2026-11-12
This study is looking at how a specific protein in the bacteria Pseudomonas aeruginosa helps it survive and resist treatments, with the goal of finding new ways to fight infections for people who are affected by this tough germ.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Eastern Washington University NIH-funded |
| Lab location | 1 site (Cheney, United States) |
| Project start | April 1, 2023 |
| Project end | March 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $99,587 |
| NIH project number | 3R15GM150043-02S1 |
| Project ID | NIH-11035787 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from infections caused by Pseudomonas aeruginosa, particularly those with compromised immune systems or chronic conditions.
✕Less likely to help
Patients with infections caused by other types of bacteria that do not involve Pseudomonas aeruginosa may not benefit from this research.
What this research studies
This research focuses on Pseudomonas aeruginosa, a bacteria that can cause severe infections in humans. The project aims to understand how a protein called NtrC helps this bacteria adapt and resist treatments, including antibiotics. By disrupting the regulatory networks that control the expression of genes related to this protein, the researchers hope to find new ways to combat the bacteria's ability to infect and damage human tissues. Patients may benefit from insights gained about how to better target this pathogen.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively combat infections caused by Pseudomonas aeruginosa.
How similar studies have gone: While the specific approach of targeting the NtrC protein is novel, similar research has shown promise in understanding bacterial resistance mechanisms.
Where this research is happening
-
Eastern Washington University
Cheney, United States Active
Researchers
- Principal investigator: Sarwar, Zaara — Eastern Washington University
- Study coordinator: Sarwar, Zaara
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.